COST-EFFECTIVENESS OF RESPIRATORY SYNCYTIAL VIRUS PROPHYLAXIS WITH PALIVIZUMAB AMONG PRETERM INFANTS COVERED BY MEDICAID IN THE UNITED STATES

被引：1
|
作者：
Weiner, L. B. [1 ]
Polak, M. J. [2 ]
Masaquel, A. [3 ]
Mahadevia, P. J. [3 ]
机构：
[1] Upstate Med Univ, Syracuse, NY USA
[2] W Virginia Univ, Sch Med, Morgantown, WV 26506 USA
[3] MedImmune, Gaithersburg, MD USA
来源：
VALUE IN HEALTH | 2011年 / 14卷 / 03期
关键词：
D O I：
10.1016/j.jval.2011.02.655
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A118 / A118
页数：1
相关论文
共 50 条
  • [21] Updated cost-effectiveness analysis of palivizumab (Synagis) for the prophylaxis of respiratory syncytial virus in infant populations in the UK
    Narayan, Omendra
    Bentley, Anthony
    Mowbray, Katie
    Hermansson, Monika
    Pivonka, Dominic
    Kemadjou, Eric Ngonga
    Belsey, Jonathan
    JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (12) : 1640 - 1652
  • [22] Palivizumab for prophylaxis of respiratory syncytial virus infections in preterm neonates
    Gortner, Ludwig
    KLINISCHE PADIATRIE, 2017, 229 (05): : 259 - 260
  • [23] COST EFFECTIVENESS OF PALIVIZUMAB FOR RESPIRATORY SYNCYTIAL VIRUS PROPHYLAXIS AMONG EXTREME PRETERM INFANTS (29 WEEKS OF GESTATIONAL AGE) AT THE SOCIAL SECURITY MEXICAN INSTITUTE (IMSS)
    Paladio Hernandez, J. A.
    Lagunas-Quiroz, J., I
    Matias-Juan, N. A.
    VALUE IN HEALTH, 2020, 23 : S156 - S156
  • [24] Cost-effectiveness analysis of palivizumab for respiratory syncytial virus infection in high-risk infants in Japan
    Ikeda, S.
    Kobayashi, M.
    VALUE IN HEALTH, 2007, 10 (03) : A170 - A170
  • [25] Adherence to Palivizumab for Respiratory Syncytial Virus Prophylaxis in Romanian Infants
    Calomfirescu-Avramescu, Andreea
    Toma, Adrian Ioan
    Mehedintu, Claudia
    Nastase, Leonard
    Dima, Vlad
    VACCINES, 2025, 13 (02)
  • [26] Effectiveness of palivizumab immunoprophylaxis in preterm infants against respiratory syncytial virus disease in Qatar
    Abushahin, Ahmad
    Janahi, Ibrahim
    Tuffaha, Amjad
    INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2018, 11 : 41 - 46
  • [27] COST-EFFECTIVENESS ANALYSIS OF PALIVIZUMAB WITH RISK FACTORS FOR RESPIRATORY SYNCYTIAL VIRUS PREVENTION
    Lee, M. Y.
    Lee, E. K.
    VALUE IN HEALTH, 2012, 15 (07) : A398 - A398
  • [28] The Cost-Effectiveness of Palivizumab in the Prevention of Respiratory Syncytial Virus Bronchiolitis: A Systematic Review
    Blanken, Maarten
    Bont, Louis
    Rovers, Maroeska
    CURRENT RESPIRATORY MEDICINE REVIEWS, 2011, 7 (03) : 203 - 212
  • [29] Cost-effectiveness of Respiratory Syncytial Virus Prophylaxis in Various Indications
    Hampp, Christian
    Kauf, Teresa L.
    Saidi, Arwa S.
    Winterstein, Almut G.
    ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE, 2011, 165 (06): : 498 - 505
  • [30] Palivizumab prophylaxis for respiratory syncytial virus in infants with cystic fibrosis: is there a need?
    Candice Bjornson
    Parco Chan
    Abby Li
    Bosco Paes
    Krista L. Lanctôt
    Ian Mitchell
    European Journal of Clinical Microbiology & Infectious Diseases, 2018, 37 : 1113 - 1118
12345